The purpose of this study is to learn more about chronic constipation in Down syndrome to benefit those suffering from this condition and improve future treatments.
Anyone who has or does not have Down syndrome and has been diagnosed with chronic constipation that is not due to a known congenital condition may be eligible.
The Neurogastroenterology and Motility Program at Children's Hospital Colorado offers specialized treatments for chronic constipation including an expert motility physician, occupational and pelvic physical therapy, and a pediatric psychologist that are all typically covered by insurance.
Compensation is provided.
Collaborating Physician: Jaime Belkind-Gerson, MD, MSc
PI: Joaquin Espinosa, PhD
Want more information? Check out an expert Q&A featuring the study's collaborating physician Dr. Jaime Belkind-Gerson and investigator Dr. Kelly Sullivan.
The purpose of this research is to determine the safety and effectiveness of different potential treatments for DSRD.
Individuals with Down syndrome between the age of 8 and 30 years may be eligible to participate if they have symptoms or a diagnosis of DSRD. Participants must be accompanied by a study partner and agree to a randomized treatment assignment.
Compensation is provided and travel funds are available if needed.
PIs: Joaquin Espinosa, PhD; Elise Sannar, MD; Jonathon Santoro, MD | NCT05662228
Want more information? Check out our Down Syndrome Regression Disorder Clinical Trial research page to learn more about the science behind this study.
The purpose of this research is to determine whether tofacitinib is a safe and effective treatment for immune skin conditions in people with Down syndrome, and to further our understanding of the immune system in Down syndrome.
Adolescents and adults with Down syndrome between the age of 12 and 50 years may be eligible to participate if they have an active immune skin condition. For example: eczema or atopic dermatitis, alopecia areata, hidradenitis suppurativa, psoriasis, or vitiligo.
Compensation is provided and travel funds are available if needed.
PI: Joaquin Espinosa. COMIRB #19-1362. NCT04246372.
Want more information? Check out our Immune Skin Conditions Clinical Trial research page to learn more about the science behind this study.
The purpose of this study is to provide qualified and approved researchers with access to biological samples and health information to answer specific research questions. This project will significantly increase the speed of Down syndrome research and the understanding of associated medical conditions such as leukemia and Alzheimer’s disease.
Who can participate? Anyone 6 months to 89 years old who: (1) has Down syndrome, or (2) has a family member with Down syndrome, or (3) does not have Down syndrome.
PI: Joaquin Espinosa. COMIRB# 15-2170. NCT02864108.
Want more information? Check out our www.trisome.org website to learn more about the science enabled by the Biobank.
As many as 9 in 10 people with Down syndrome develop Alzheimer’s disease.
The Trial-Ready Cohort-Down Syndrome, or TRC-DS, matches people with Down syndrome to clinical trials targeting Down-syndrome related Alzheimer’s disease. It is a national clinical study, and the Linda Crnic Institute for Down Syndrome is a qualified participation site near Denver, Colorado.
TRC-DS needs 120 healthy people between the ages of 35 and 55 with Down syndrome.
Because Alzheimer’s disease affects people with Down syndrome at a much earlier age than the general population, researchers are looking for volunteers 35 to 55 years old to participate in research.
The University of Colorado Alzheimer's and Cognition Center is focused on understanding the aging process and has significant expertise in the relationship between Alzheimer's disease and Dow syndrome
If someone you know has Down syndrome and is 30 years or older:
He or she may be eligible to participate in a research study designed to enhance our understanding of the causes of Alzheimer's disease and other diseases that cause memory and thinking problems and to potentially uncover new approaches to treating these disease.
This study will involve one visit per year to the University of Colorado Anschutz Medical Campus in Aurora, CO.
During each research visit, the participant will:
PI: Brianne Bettcher, PhD COMIRB#: 15-1774